ResearchPeptide

ARA-290

Published Research

PubMed-indexed studies for ARA-290

Research

ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.

Molecular medicine (Cambridge, Mass.) 2015

View on PubMed →

Research

Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression.

Brain, behavior, and immunity 2022

View on PubMed →

Research

ARA 290 for treatment of small fiber neuropathy in sarcoidosis.

Expert opinion on investigational drugs 2014

View on PubMed →

Research

A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets.

Transplantation 2016

View on PubMed →

Research

ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response.

Molecular pain 2014

View on PubMed →

Research

ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception.

Peptides 2016

View on PubMed →

Research-Grade ARA-290

⚠️ For laboratory research only. Not for human use.

ARA-290

Published Research

ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.

Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression.

ARA 290 for treatment of small fiber neuropathy in sarcoidosis.

A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets.

ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response.

ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception.

Research-Grade ARA-290

Frequently Asked Questions

What are research peptides?

What does peptide purity mean and why does it matter?

What form do your peptides come in?

How should research peptides be stored?

Who can purchase research peptides?

How do you ensure peptide quality?

What does "Research Use Only" mean?

How are peptides shipped?

What is your return and refund policy?

Published Research

ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.

Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression.

ARA 290 for treatment of small fiber neuropathy in sarcoidosis.

A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets.

ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response.

ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception.

Research-Grade ARA-290

Frequently Asked Questions

What are research peptides?

What does peptide purity mean and why does it matter?

What form do your peptides come in?

How should research peptides be stored?

Who can purchase research peptides?

How do you ensure peptide quality?

What does "Research Use Only" mean?

How are peptides shipped?

What is your return and refund policy?

⚠️ Research Use Only — Legal Acknowledgment